Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07358364 · ClinicalTrials.gov registry record
Remibrutinib in Real-world Clinical Practice
A clinical trial of Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 3,280
- Enrollment target
- 1
- Study location
NCT07358364: Recruiting study of Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals.
NCT07358364 is a study of Chronic Spontaneous Urticaria that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 3,280 participants, above the 1,245-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (163% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07358364, a study of Chronic Spontaneous Urticaria, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 3,280 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, multi-country, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.
Primary Outcome
Urticaria Control Test is looking retrospectively for 7 days (UCT7) and consists of 4 questions. Each question is scored 0-4, with a total score range of 0 (poor control) to 16 (well controlled).
Conditions Studied
Study Locations (1)
Missouri
- Cleaver Dermatology - Kirksville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,280 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2031-10-30 |
What NCT07358364 shows while recruiting
NCT07358364 is an observational study that tracks outcomes without assigning an intervention. Its 3,280 participants enrollment target places it among the larger protocols in the corpus, above the 1,245-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (163% higher).
The record links to 1 condition, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 0 interventions.
NCT07358364 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07358364 about?
NCT07358364 is a clinical study titled "Remibrutinib in Real-world Clinical Practice". Prospective, multi-country, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness...
What is the current status of trial NCT07358364?
This trial is currently recruiting. The enrollment target is 3,280 participants. The study started on 2026-02-02. Estimated completion is 2031-10-30.
What conditions does trial NCT07358364 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria.
Who is sponsoring clinical trial NCT07358364?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07358364 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Spontaneous Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07358364's enrollment target sits among peer trials
3,280 2nd of 18 the highest of 18 other Chronic Spontaneous Urticaria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Spontaneous Urticaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
Remibrutinib in Real-world Clinical Practice - a US Sub-study
RECRUITING
-
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
RECRUITING · Phase 2
-
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
RECRUITING · Phase 3
-
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
RECRUITING
-
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- NCT04077762 · 3,266 participants · NA
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI